Goldman Sachs Maintains Sell on Arcturus Therapeutics, Lowers Price Target to $14
Goldman Sachs maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Sell and lowers the price target from $16 to $14.
Baird Upgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $18
Baird analyst Joel Beatty upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Underperform to Neutral and lowers the price target from $21 to $18.
Expert Ratings for Arcturus Therapeutics
Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings:
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell
• Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months after a low-dose (5 mcg) booster.
28 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) climbed 58.3% to $2.2950 after jumping around 22% on Tuesday.
Arcturus’ COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) shared topline data from an ongoing Phase 1/2/3 trial evaluating the ARCT-154, a self-amplifying mRNA COVID-19…
The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus’ COVID-19 Vaccine Trial Data, FDA Rejects Teva’s Schizophrenia Med, Otonomy Aces Hearing Loss Study
Here's a roundup of top developments in the biotech space over the last 24 hours.
Piper Comments On Increased Interest To Invest In Arcturus, ‘Incrementally Positive’ On Argenx
Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-COV19 vaccine candidate as a booster.
Citigroup Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $86
Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $114 to $86.